Nancy E Davidson

List of Publications by Citations

223 papers	37,504 citations	81 h-index	193 g-index
243 ext. papers	42,083 ext. citations	8.4 avg, IF	6.74 L-index

#	Paper	IF	Citations
223	Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *New England Journal of Medicine*, **2005**, 353, 1673-84	59.2	4284
222	Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *New England Journal of Medicine*, **2007**, 357, 2666-76	59.2	2529
221	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology*, **2013**, 24, 2206-23	10.3	2048
220	A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *New England Journal of Medicine*, **2003**, 349, 1793-802	59.2	1500
219	Estrogen carcinogenesis in breast cancer. *New England Journal of Medicine*, **2006**, 354, 270-82	59.2	1296
218	Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *Journal of Clinical Oncology*, **2003**, 21, 1431-9	2.2	1245
217	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Annals of Oncology*, **2015**, 26, 1533-46	10.3	1122
216	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncology, The*, **2010**, 11, 55-65	21.7	1065
215	Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. *Nature Genetics*, **1994**, 7, 536-40	36.3	1005
214	Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. *Journal of the National Cancer Institute*, **2005**, 97, 1262-71	9.7	918
213	Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *Journal of Clinical Oncology*, **2014**, 32, 2959-66	2.2	780
212	Weekly paclitaxel in the adjuvant treatment of breast cancer. *New England Journal of Medicine*, **2008**, 358, 1663-71	59.2	701
211	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. *Journal of Clinical Oncology*, **2015**, 33, 2563-77	2.2	599
210	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. *Journal of Clinical Oncology*, **2014**, 32, 3744-52	2.2	572
209	American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. *Journal of Clinical Oncology*, **2010**, 28, 3784-96	2.2	565
208	Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. *Journal of Clinical Oncology*, **2011**, 29, 3366-73	2.2	555
207	Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. *Journal of Clinical Oncology*, **2014**, 32, 2255-69	2.2	545

206	Adjuvant ovarian suppression in premenopausal breast cancer. *New England Journal of Medicine*, **2015**, 372, 436-46	59.2	462
205	Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. *Journal of Clinical Oncology*, **2008**, 26, 1231-8	2.2	424
204	Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. *Journal of Clinical Oncology*, **2013**, 31, 961-5	2.2	414
203	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. *Journal of Clinical Oncology*, **2016**, 34, 2925-34	2.2	384
202	Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. *Molecular Endocrinology*, **1988**, 2, 543-55		381
201	HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. *Journal of Clinical Oncology*, **2006**, 24, 3032-8	2.2	376
200	A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. *Journal of the National Cancer Institute*, **2013**, 105, 701-10	9.7	353
199	Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. *Journal of the National Cancer Institute*, **2002**, 94, 855-7	9.7	323
198	Anticancer activities of novel chalcone and bis-chalcone derivatives. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3491-5	3.4	305
197	Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. *Lancet, The*, **2001**, 357, 1335-6	40	295
196	Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. *Journal of Clinical Oncology*, **2009**, 27, 5319-24	2.2	285
195	Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. *Journal of Clinical Oncology*, **2008**, 26, 4063-71	2.2	271
194	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *New England Journal of Medicine*, **2018**, 379, 122-137	59.2	270
193	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. *Journal of Clinical Oncology*, **2014**, 32, 2078-99	2.2	270
192	Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. *Molecular Cancer Therapeutics*, **2007**, 6, 1013-21	6.1	256
191	Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. *Carcinogenesis*, **2007**, 28, 1485-90	4.6	256
190	Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. *Journal of Medicinal Chemistry*, **2003**, 46, 2813-5	8.3	249
189	Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. *Molecular Endocrinology*, **1987**, 1, 216-23		239

188	Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. *Journal of Clinical Oncology*, **2013**, 31, 2942-62	2.2	230
187	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. *Journal of Clinical Oncology*, **2019**, 37, 423-438	2.2	218
186	American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. *Journal of Clinical Oncology*, **1999**, 17, 1080-2	2.2	214
185	Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. *Journal of Clinical Oncology*, **2011**, 29, 4491-7	2.2	202
184	Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. *Journal of Clinical Oncology*, **2008**, 26, 2473-81	2.2	190
183	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*, **2014**, 32, 3307-29	2.2	185
182	Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). *Journal of Clinical Oncology*, **2005**, 23, 5973-82	2.2	184
181	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. *Journal of Clinical Oncology*, **2016**, 34, 1689-701	2.2	179
180	Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. *Journal of Clinical Oncology*, **2009**, 27, 5911-8	2.2	178
179	HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. *Journal of Clinical Oncology*, **2010**, 28, 4307-15	2.2	175
178	Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. *Journal of Clinical Oncology*, **2004**, 22, 4683-90	2.2	174
177	Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. *Clinical Cancer Research*, **2008**, 14, 1938-46	12.9	173
176	Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. *Cancer Research*, **2006**, 66, 6370-8	10.1	173
175	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. *Journal of Clinical Oncology*, **2015**, 33, 3938-44	2.2	158
174	Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. *Journal of Clinical Oncology*, **2008**, 26, 1948-55	2.2	156
173	The biology of breast carcinoma. *Cancer*, **2003**, 97, 825-33	6.4	155
172	Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. *Breast Cancer Research and Treatment*, **2012**, 132, 175-87	4.4	148
171	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. *Clinical Cancer Research*, **2016**, 22, 1130-7	12.9	144

170	Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. *Cancer*, **2012**, 118, 5937-46	6.4	138
169	A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2Qdeoxycytidine. *Breast Cancer Research and Treatment*, **2003**, 81, 177-86	4.4	138
168	The loss of estrogen and progesterone receptor gene expression in human breast cancer. *Journal of Mammary Gland Biology and Neoplasia*, **1998**, 3, 85-94	2.4	137
167	Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. *Molecular Endocrinology*, **2005**, 19, 1740-51		136
166	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. *Journal of Clinical Oncology*, **2015**, 33, 2353-60	2.2	135
165	Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. *Molecular Cancer Research*, **2008**, 6, 873-83	6.6	131
164	Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. *Journal of Clinical Oncology*, **2014**, 32, 2100-8	2.2	129
163	Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. *Cancer Biology and Therapy*, **2007**, 6, 64-9	4.6	127
162	Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2Qdeoxycytidine-induced cytotoxicity in human breast cancer cells. *Journal of Biological Chemistry*, **1997**, 272, 32260-6	5.4	122
161	Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. *Journal of Clinical Oncology*, **2007**, 25, 2006-11	2.2	112
160	Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. *Clinical Cancer Research*, **2006**, 12, 3306-10	12.9	110
159	Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. *Journal of Clinical Oncology*, **2004**, 22, 3700-4	2.2	108
158	MCF-7 cells--changing the course of breast cancer research and care for 45 years. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	107
157	Future cancer research priorities in the USA: a Lancet Oncology Commission. *Lancet Oncology, The*, **2017**, 18, e653-e706	21.7	106
156	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology*, **2018**, 36, 2736-2740	2.2	103
155	Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. *Breast Cancer Research and Treatment*, **2010**, 120, 581-92	4.4	102
154	Transforming Cancer Prevention through Precision Medicine and Immune-oncology. *Cancer Prevention Research*, **2016**, 9, 2-10	3.2	101
153	Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. *Journal of Biological Chemistry*, **2005**, 280, 18302-10	5.4	99

152	Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. *Breast Cancer Research and Treatment*, **2012**, 131, 777-89	4.4	96
151	Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. *JAMA Oncology*, **2017**, 3, 666-671	13.4	95
150	Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. *Journal of Clinical Oncology*, **2013**, 31, 2115-22	2.2	95
149	Epigenetics in breast cancer: what's new?. *Breast Cancer Research*, **2011**, 13, 225	8.3	92
148	Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. *Cancer Research*, **2014**, 74, 1463-74	10.1	89
147	Spermine oxidase SMO(PAOh1), Not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines. *Journal of Biological Chemistry*, **2005**, 280, 39843-51	5.4	87
146	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. *Clinical Cancer Research*, **2017**, 23, 2691-2701	12.9	84
145	Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. *Cancer Research*, **2007**, 67, 5337-44	10.1	83
144	Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. *Journal of Clinical Oncology*, **2008**, 26, 4092-9	2.2	82
143	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 2736-41	11.5	81
142	Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. *Breast Cancer Research*, **2017**, 19, 60	8.3	80
141	Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. *Clinical Cancer Research*, **2015**, 21, 5082-5091	12.9	79
140	Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. *Cancer Biology and Therapy*, **2003**, 2, 552-6	4.6	78
139	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. *Breast Cancer Research and Treatment*, **2006**, 99, 295-300	4.4	77
138	Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. *Carcinogenesis*, **2013**, 34, 1196-207	4.6	74
137	A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. *Clinical Cancer Research*, **2003**, 9, 5922-8	12.9	71
136	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. *Oncogene*, **2019**, 38, 390-405	9.2	68
135	Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. *Journal of Clinical Oncology*, **2012**, 30, 3051-7	2.2	68

134	Molecular mechanisms of polyamine analogs in cancer cells. *Anti-Cancer Drugs*, **2005**, 16, 229-41	2.4	68
133	Primary systemic therapy in operable breast cancer. *Journal of Clinical Oncology*, **2000**, 18, 1558-69	2.2	67
132	Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. *Journal of Mammary Gland Biology and Neoplasia*, **2001**, 6, 183-92	2.4	66
131	Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. *Journal of the National Cancer Institute*, **2012**, 104, 406-14	9.7	65
130	Epigenetic regulation as a new target for breast cancer therapy. *Cancer Investigation*, **2007**, 25, 659-65	2.1	64
129	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology*, **2019**, 37, 3152-3165	2.2	63
128	Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. *Science Translational Medicine*, **2014**, 6, 229ra41	17.5	63
127	Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. *Breast Cancer Research and Treatment*, **2010**, 124, 585-91	4.4	63
126	Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. *Amino Acids*, **2012**, 42, 887-98	3.5	61
125	Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. *Journal of the National Cancer Institute*, **2012**, 104, 159-62	9.7	61
124	A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. *Clinical Cancer Research*, **2008**, 14, 6277-83	12.9	59
123	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology*, **2018**, 36, 2804-2807	2.2	59
122	Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. *Carcinogenesis*, **2010**, 31, 382-7	4.6	58
121	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. *Breast Cancer Research and Treatment*, **2012**	4.4	55
120	Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. *Breast Cancer Research and Treatment*, **2009**, 117, 443-51	4.4	54
119	A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. *Cancer Immunology Research*, **2014**, 2, 949-61	12.5	51
118	A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. *Breast Cancer Research and Treatment*, **2012**, 131, 915-24	4.4	50
117	C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. *Journal of Clinical Oncology*, **2011**, 29, 651-9	2.2	49

116	A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. *Clinical Cancer Research*, **2003**, 9, 2769-77	12.9	49
115	The follow-up of breast cancer. *Seminars in Oncology*, **2003**, 30, 338-48	5.5	48
114	American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. *Journal of Clinical Oncology*, **2011**, 29, 3939-42	2.2	47
113	Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. *Clinical Cancer Research*, **2013**, 19, 1281-9	12.9	46
112	Practical Approach to Triple-Negative Breast Cancer. *Journal of Oncology Practice*, **2017**, 13, 293-300	3.1	45
111	Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. *Breast Cancer Research and Treatment*, **2012**, 131, 907-14	4.4	45
110	Methyl-group dietary intake and risk of breast cancer among African-American women: a case-control study by methylation status of the estrogen receptor alpha genes. *Cancer Causes and Control*, **2003**, 14, 827-36	2.8	45
109	Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. *Clinical Cancer Research*, **2017**, 23, 43-51	12.9	44
108	Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (□Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. *Academic Radiology*, **2010**, 17, 1477-85	4.3	42
107	Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 5362-5369	12.9	42
106	Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. *Proteomics*, **2010**, 10, 1029-39	4.8	41
105	PI3 kinase activation and response to Trastuzumab Therapy: what□neu with herceptin resistance?. *Cancer Cell*, **2007**, 12, 297-9	24.3	41
104	Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. *Breast Cancer Research and Treatment*, **2014**, 146, 99-108	4.4	40
103	Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. *Molecular Oncology*, **2012**, 6, 222-36	7.9	39
102	Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. *Cancer*, **2013**, 119, 2675-82	6.4	39
101	Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth. *Journal of Biological Chemistry*, **2018**, 293, 1120-1137	5.4	39
100	The molecular landscape of premenopausal breast cancer. *Breast Cancer Research*, **2015**, 17, 104	8.3	38
99	HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. *International Journal of Cancer*, **2018**, 143, 1388-1401	7.5	38

98	Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. *Journal of the National Cancer Institute*, **1990**, 82, 570-4	9.7	37
97	Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells. *Journal of Biological Chemistry*, **2006**, 281, 19055-63	5.4	36
96	Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. *Technology in Cancer Research and Treatment*, **2004**, 3, 543-50	2.7	36
95	Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability. *Journal of Biological Chemistry*, **2005**, 280, 29519-24	5.4	35
94	Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells. *Oncogene*, **1999**, 18, 7453-61	9.2	35
93	Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. *Cancer Research*, **2018**, 78, 6209-6222	10.1	35
92	Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). *British Journal of Cancer*, **2015**, 113, 1651-7	8.7	34
91	The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. *Cancer Chemotherapy and Pharmacology*, **2010**, 65, 1067-81	3.5	34
90	Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. *Oncogene*, **1998**, 17, 577-83	9.2	34
89	Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells. *Breast Cancer Research and Treatment*, **2012**, 136, 57-66	4.4	33
88	Regulation of estrogen receptor alpha function in breast cancer. *Critical Reviews in Oncogenesis*, **1997**, 8, 29-46	1.3	33
87	WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. *Breast Cancer Research*, **2016**, 18, 92	8.3	32
86	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. *Nature Communications*, **2019**, 10, 5114	17.4	32
85	What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?. *Oncologist*, **2004**, 9, 507-17	5.7	32
84	Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. *Cancer Biology and Therapy*, **2004**, 3, 1304-12	4.6	30
83	Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. *Carcinogenesis*, **2013**, 34, 2587-92	4.6	29
82	Regulation of Polyamine Analogue Cytotoxicity by c-Jun in Human MDA-MB-435 Cancer Cells. *Molecular Cancer Research*, **2004**, 2, 81-88	6.6	28
81	Induction of spermidine/spermine N1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N1, N11-diethylnorspermine. *Cancer Chemotherapy and Pharmacology*, **2004**, 54, 122-6	3.5	27

80	The biology of breast cancer. *Hematology/Oncology Clinics of North America*, **1999**, 13, 311-32	3.1	27
79	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. *JAMA Oncology*, **2020**, 6, 505-511	13.4	27
78	AACR Cancer Progress Report 2016. *Clinical Cancer Research*, **2016**, 22 Suppl 19, S1-S137	12.9	27
77	A metastasis biomarker (MetaSite Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. *Npj Breast Cancer*, **2017**, 3, 42	7.8	26
76	Novel insight into KLF4 proteolytic regulation in estrogen receptor signaling and breast carcinogenesis. *Journal of Biological Chemistry*, **2012**, 287, 13584-97	5.4	26
75	Of Snail, mice, and women. *Cancer Cell*, **2005**, 8, 173-4	24.3	25
74	Monoclonal antibody cocktail as an enrichment tool for acetylome analysis. *Analytical Chemistry*, **2011**, 83, 3623-6	7.8	24
73	Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. *Oncotarget*, **2017**, 8, 81737-81753	3.3	24
72	Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. *Journal of Clinical Oncology*, **2016**, 34, 1580-3	2.2	23
71	Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. *Clinical Cancer Research*, **2013**, 19, 4008-16	12.9	21
70	Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. *Clinical Cancer Research*, **2009**, 15, 7693-7700	12.9	21
69	Integrated proteomic and metabolic analysis of breast cancer progression. *PLoS ONE*, **2013**, 8, e76220	3.7	21
68	Trastuzumab in breast cancer. *Oncology*, **2004**, 18, 1117-28; discussion 1131-2, 1137-8	1.8	21
67	Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. *Oncology Nursing Forum*, **2014**, 41, 660-8	1.7	20
66	Adjuvant hormonal therapy for premenopausal women with breast cancer. *Seminars in Oncology*, **2006**, 33, 657-63	5.5	19
65	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. *Journal of Oncology Practice*, **2018**, 14, 501-504	3.1	19
64	AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. *Cancer Prevention Research*, **2018**, 11, 735-778	3.2	19
63	A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. *Hormones and Cancer*, **2015**, 6, 214-24	5	18

62	Epigenetic reprogramming in breast cancer: from new targets to new therapies. *Annals of Medicine*, **2014**, 46, 397-408	1.5	18
61	Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. *Breast*, **2013**, 22 Suppl 2, S165-70	3.6	18
60	Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. *Clinical Cancer Research*, **2013**, 19, 5798-807	12.9	18
59	Epigenetics meets estrogen receptor: regulation of estrogen receptor by direct lysine methylation. *Endocrine-Related Cancer*, **2009**, 16, 319-23	5.7	18
58	Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. *Clinical Cancer Research*, **2011**, 17, 7194-203	12.9	18
57	Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, 23-32	7.1	18
56	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. *Breast Cancer Research*, **2015**, 17, 133	8.3	17
55	Ovarian ablation as adjuvant therapy for breast cancer. *Seminars in Oncology*, **2001**, 28, 322-331	5.5	17
54	Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. *Breast Cancer Research and Treatment*, **2015**, 153, 311-21	4.4	16
53	Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition. *Cancer Prevention Research*, **2015**, 8, 1000-9	3.2	15
52	Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. *Breast*, **2015**, 24 Suppl 2, S120-5	3.6	15
51	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 153-62	4.4	15
50	Aromatase inhibitors for breast cancer. *Reviews in Endocrine and Metabolic Disorders*, **2007**, 8, 215-28	10.5	15
49	Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. *Journal of Clinical Oncology*, **2006**, 24, 2392-4; author reply 2394-5	2.2	15
48	Role of p53/p21(Waf1/Cip1) in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. *Cancer Biology and Therapy*, **2005**, 4, 1006-13	4.6	15
47	Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. *Scientific Reports*, **2018**, 8, 17313	4.9	15
46	Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. *Meta Gene*, **2015**, 4, 129-41	0.7	14
45	The silent estrogen receptor--can we make it speak?. *Cancer Biology and Therapy*, **2009**, 8, 485-96	4.6	14

44	Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. *Journal of Clinical Oncology*, **2009**, 27, 2816-22	2.2	13
43	Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. *Cellular and Molecular Life Sciences*, **2014**, 71, 1549	10.3	12
42	Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells. *Molecular Cancer Research*, **2004**, 2, 81-8	6.6	12
41	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. *Journal of Clinical Oncology*, **2021**, 39, 3938-3958	2.2	11
40	New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. *Clinical Cancer Research*, **2017**, 23, 1126-1131	12.9	10
39	Hematopoietic growth factors: personalization of risks and benefits. *Molecular Oncology*, **2012**, 6, 237-41	7.9	10
38	TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. *Breast Cancer Research and Treatment*, **2012**, 134, 751-7	4.4	10
37	Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. *Breast Cancer Research and Treatment*, **1993**, 28, 277-84	4.4	10
36	Can circulating tumor cells predict resistance in metastatic breast cancer?. *Clinical Cancer Research*, **2015**, 21, 2421-3	12.9	9
35	What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. *Current Oncology Reports*, **2009**, 11, 45-50	6.3	9
34	Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.. *Journal of Clinical Oncology*, **2012**, 30, 1005-1005	2.2	9
33	Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma. *Scientific Reports*, **2020**, 10, 11487	4.9	9
32	Apoptosis in hormone-responsive malignancies. *Advances in Pharmacology*, **1997**, 41, 553-83	5.7	7
31	Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. *Clinical Breast Cancer*, **2006**, 6, 525-9	3	7
30	The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future. *Journal of Clinical Oncology*, **2010**, 28, 1616-21	2.2	5
29	Silencing estrogen receptor alpha in breast cancer cells. *Cancer Biology and Therapy*, **2006**, 5, 848-9	4.6	5
28	The regulation of estrogen receptor expression and function in human breast cancer. *Cancer Treatment and Research*, **1998**, 94, 255-78	3.5	5
27	HER2-targeted therapies: how far we've come--and where we're headed. *Oncology*, **2011**, 25, 425-6	1.8	5

26	Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer. *Journal of Clinical Oncology*, **2006**, 24, 4949-51	2.2	4
25	Use of SERMs for the adjuvant therapy of early-stage breast cancer. *Annals of the New York Academy of Sciences*, **2001**, 949, 80-8	6.5	4
24	Inhibition of histone deacetylases. *Methods in Molecular Biology*, **2011**, 791, 297-311	1.4	4
23	Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?. *Clinical Cancer Research*, **2016**, 22, 4963-4965	12.9	3
22	Breast cancer: The 21-gene recurrence score - biology remains at the forefront. *Nature Reviews Clinical Oncology*, **2016**, 13, 470-2	19.4	3
21	D□vu for breast cancer two?. *Journal of the National Cancer Institute*, **2004**, 96, 497-9	9.7	3
20	Case records of the Massachusetts General Hospital. Case 35-2005. A 56-year-old woman with breast cancer and isolated tumor cells in a sentinel lymph node. *New England Journal of Medicine*, **2005**, 353, 2177-85	59.2	3
19	The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility. *Clinical Cancer Research*, **2020**, 26, 5543-5545	12.9	3
18	Postoperative endocrine therapy for invasive breast cancer. *Cancer Treatment and Research*, **2009**, 151, 139-61	3.5	3
17	Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era. *Journal of the National Cancer Institute*, **2019**, 111, 641-643	9.7	2
16	New findings about endocrine therapy for breast cancer. *Breast*, **2003**, 12, 368-72	3.6	2
15	Optimal duration of trastuzumab for early HER2-positive breast cancer. *Lancet, The*, **2017**, 389, 1167-1168	60	1
14	Reply to J.M. Guinebretiere and L. Arnould et al. *Journal of Clinical Oncology*, **2009**, 27, 2734-2735	2.2	1
13	Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer. *Journal of the National Cancer Institute*, **2009**, 101, 698-9	9.7	1
12	How we maintain bone health in early-stage breast cancer patients on aromatase inhibitors. *Journal of Oncology Practice*, **2007**, 3, 323-5	3.1	1
11	Proteomic and Transcriptomic Profiling Identifies Mediators of Anchorage-Independent Growth and Roles of Inhibitor of Differentiation Proteins in Invasive Lobular Breast Cancer		1
10	Apoptosis and Breast Cancer **1999**, 291-303		1
9	Conquering Metastatic Breast Cancer. *Journal of Oncology Practice*, **2016**, 12, 11-2	3.1	1

8	Gonadotropin-Releasing Hormone (GnRH) Agonists for Fertility Preservation: Is POEMS the Final Verse?. *Journal of the National Cancer Institute*, **2019**, 111, 107-108	9.7	1
7	Incident Cancer in Cancer Survivors-When Cancer Lurks in the Background. *JAMA Oncology*, **2018**, 4, 836-837	8.4	1
6	Optimal adjuvant endocrine therapy for breast cancer. *Lancet Oncology, The*, **2021**, 22, 1357-1358	21.7	0
5	What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. *Current Breast Cancer Reports*, **2009**, 1, 42-47	0.8	
4	Epigenetic Regulation as a New Target for Breast Cancer Therapy. *Translational Medicine Series*, **2007**, 285-296		
3	Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. *Cancer*, **2020**, 126, 5239-5246	6.4	
2	Reply to C. Shah et al. *Journal of Clinical Oncology*, **2016**, 34, 1824-5	2.2	
1	Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. *Cancer Investigation*, **2021**, 39, 21-24	2.1	